Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18962307 | 0.91 | TSHR (0.52) | ANPEPPLAUTSHRSLC18A3 | |
| SCHEMBL2943529 | 0.87 | ANPEP (0.57) | ANPEPPLAUTSHRMTNR1AMTNR1B | |
| SCHEMBL291460 | 0.87 | ANPEP (0.57) | ANPEPPLAUTSHRMTNR1AMTNR1B | |
| SCHEMBL13998125 | 0.87 | ANPEP (0.57) | ANPEPPLAUTSHRMTNR1AMTNR1B | |
| SCHEMBL6951241 | 0.87 | ANPEP (0.57) | ANPEPPLAUTSHRMTNR1AMTNR1B | |
| SCHEMBL20445626 | 0.87 | TSHR (0.54) | ANPEPPLAUTSHRSLC18A3 | |
| Water SCHEMBL22090286 | 0.85 | ANPEP (0.55) | ANPEPPLAUMTNR1AMTNR1BCA1 | |
| Ammonia Solution, Strong SCHEMBL6107709 | 0.85 | ANPEP (0.55) | ANPEPPLAUMTNR1AMTNR1BCA1 | |
| Iodide SCHEMBL10818108 | 0.84 | ANPEP (0.53) | ANPEPPLAUMTNR1AMTNR1BCA1 | |
| Cyclohexanol SCHEMBL11330945 | 0.80 | TSHR (0.59) | ANPEPTSHRSLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | claimed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | KANEKA CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1445324-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMAN DERIVATIVE AND INTERMEDIATE | KANEKA CORPORATION (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | CYP8B1, CYP3A43, HPD | ANPEP 1934/4885PLAU 616/4885TSHR 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.